Molecular Markers and Targets in Melanoma

por Teixido, Cristina, Castillo, Paola, Martinez-Vila, Clara, Arance, Ana, Alos, Llucia
Publicado 2021

Implementation of an NGS panel for clinical practice in paraffin-embedded tissue samples from locally advanced and metastatic melanoma patients

por Castillo, Paola, Marginet, Marta, Jares, Pedro, García, Mireia, Gonzalvo, Elena, Arance, Ana, García, Adriana, Alos, Llucia, Teixido, Cristina
Publicado 2020

Initial Stage of Cutaneous Primary Melanoma Plays a Key Role in the Pattern and Timing of Disease Recurrence

por ERTEKIN, Sümeyre Seda, PODLIPNIK, Sebastian, RIQUELME-MC LOUGHLIN, Constanza, BARREIRO-CAPURRO, Alicia, ARANCE, Ana, CARRERA, Cristina, MALVEHY, Josep, PUIG, Susana
Publicado 2021

Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study)

por McArthur, Grant A., Mohr, Peter, Ascierto, Paolo Antonio, Arance, Ana, Banos Hernaez, Ana, Kaskel, Peter, Weichenthal, Michael, Shinde, Reshma, Stevinson, Kendall
Publicado 2017

Onset of fulminant type 1 diabetes mellitus following hypophysitis after discontinuation of combined immunotherapy. A case report

por Boswell, Laura, Casals, Gregori, Blanco, Jesús, Jiménez, Amanda, Aya, Francisco, de Hollanda, Ana, Halperin, Irene, Arance, Ana M, Mora, Mireia, Hanzu, Felicia A
Publicado 2021

Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program

por Berrocal, Alfonso, Arance, Ana, Lopez Martin, Jose Antonio, Soriano, Virtudes, Muñoz, Eva, Alonso, Lorenzo, Espinosa, Enrique, Lopez Criado, Pilar, Valdivia, Javier, Martin Algarra, Salvador
Publicado 2014

TP53 mutation and tumoral PD-L1 expression are associated with depth of invasion in desmoplastic melanomas

por Alos, Llucia, Fuster, Carla, Castillo, Paola, Jares, Pedro, Garcia-Herrera, Adriana, Marginet, Marta, Agreda, Fernando, Arance, Ana, Gonzalvo, Elena, Garcia, Mireia, Puig, Susana, Teixido, Cristina
Publicado 2020

Timeline of Adverse Events during Immune Checkpoint Inhibitors for Advanced Melanoma and Their Impacts on Survival

por Villa-Crespo, Lorena, Podlipnik, Sebastian, Anglada, Natalia, Izquierdo, Clara, Giavedoni, Priscila, Iglesias, Pablo, Dominguez, Mireia, Aya, Francisco, Arance, Ana, Malvehy, Josep, Puig, Susana, Carrera, Cristina
Publicado 2022

Life-threatening colitis and complete response with ipilimumab in a patient with metastatic BRAF-mutant melanoma and rheumatoid arthritis

por Aya, Francisco, Gaba, Lydia, Victoria, Ivan, Fernandez-Martinez, Aranzazu, Ruiz-Esquide, Virginia, Pineda, Estela, Tosca, Monica, Viladot, Margarita, Pereira, Veronica, Malvehy, Josep, Prat, Aleix, Arance, Ana
Publicado 2016

Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006

por Hamid, Omid, Robert, Caroline, Ribas, Antoni, Hodi, F. Stephen, Walpole, Euan, Daud, Adil, Arance, Ana S., Brown, Ewan, Hoeller, Christoph, Mortier, Laurent, Schachter, Jacob, Long, Jianmin, Ebbinghaus, Scot, Ibrahim, Nageatte, Butler, Marcus
Publicado 2018

Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy

por Prat, Aleix, Fan, Cheng, Fernández, Aranzazu, Hoadley, Katherine A., Martinello, Rossella, Vidal, Maria, Viladot, Margarita, Pineda, Estela, Arance, Ana, Muñoz, Montserrat, Paré, Laia, Cheang, Maggie C. U., Adamo, Barbara, Perou, Charles M.
Publicado 2015

Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East

por Ascierto, Paolo Antonio, Orlova, Kristina, Grignani, Giovanni, Dudzisz‐Śledź, Monika, Fenig, Eyal, Chiarion Sileni, Vanna, Fazio, Nicola, Samimi, Mahtab, Mortier, Laurent, Gebhardt, Christoffer, Kramkimel, Nora, Steven, Neil, Bechter, Oliver, Arance, Ana, Benincasa, Elena, Kostkova, Lenka, Costa, Nuno, Lorigan, Paul
Publicado 2021

Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial

por Ascierto, Paolo A., Dummer, Reinhard, Gogas, Helen J., Arance, Ana, Mandala, Mario, Liszkay, Gabriella, Garbe, Claus, Schadendorf, Dirk, Krajsova, Ivana, Gutzmer, Ralf, Chiarion-Sileni, Vanna, Dutriaux, Caroline, de Groot, Jan Willem B., Yamazaki, Naoya, Loquai, Carmen, Robert, Caroline, Flaherty, Keith T.
Publicado 2023

Genomic analysis and clinical management of adolescent cutaneous melanoma

por Rabbie, Roy, Rashid, Mamunur, Arance, Ana M., Sánchez, Marcelo, Tell‐Marti, Gemma, Potrony, Miriam, Conill, Carles, van Doorn, Remco, Dentro, Stefan, Gruis, Nelleke A., Corrie, Pippa, Iyer, Vivek, Robles‐Espinoza, Carla Daniela, Puig‐Butille, Joan A., Puig, Susana, Adams, David J.
Publicado 2017

A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Ind...

por Atkinson, Victoria G., Quaglino, Pietro, Aglietta, Massimo, Del Vecchio, Michele, Depenni, Roberta, Consoli, Francesca, Bafaloukos, Dimitrios, Ferrucci, Pier Francesco, Tulyte, Skaiste, Krajsová, Ivana, Ascierto, Paolo A., Gueli, Rossana, Arance, Ana, Gogas, Helen, Banerjee, Hiya, Saliba, Teddy, de Jong, Egbert, Neyns, Bart
Publicado 2021

Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629

por Bratland, Åse, Munoz-Couselo, Eva, Mortier, Laurent, Roshdy, Osama, González, Rene, Schachter, Jacob, Arance, Ana M., Grange, Florent, Meyer, Nicolas, Joshi, Abhishek Jagdish, Billan, Salem, Hughes, Brett G. M., Grob, Jean-Jacques, Ramakrishnan, Karthik, Ge, Joy, Gumuscu, Burak, Swaby, Ramona F., Gutzmer, Ralf
Publicado 2023

Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study

por Dalle, Stéphane, Mortier, Laurent, Corrie, Pippa, Lotem, Michal, Board, Ruth, Arance, Ana María, Meiss, Frank, Terheyden, Patrick, Gutzmer, Ralf, Buysse, Brian, Oh, Kelly, Brokaw, Jane, Le, T. Kim, Mathias, Susan D., Scotto, Julie, Lord-Bessen, Jennifer, Moshyk, Andriy, Kotapati, Srividya, Middleton, Mark R.
Publicado 2021

COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600–Mutant Melanoma

por Dummer, Reinhard, Flaherty, Keith T., Robert, Caroline, Arance, Ana, de Groot, Jan Willem B., Garbe, Claus, Gogas, Helen J., Gutzmer, Ralf, Krajsová, Ivana, Liszkay, Gabriella, Loquai, Carmen, Mandalà, Mario, Schadendorf, Dirk, Yamazaki, Naoya, di Pietro, Alessandra, Cantey-Kiser, Jean, Edwards, Michelle, Ascierto, Paolo A.
Publicado 2022

Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006

por Hamid, Omid, Robert, Caroline, Daud, Adil, Carlino, Matteo S., Mitchell, Tara C., Hersey, Peter, Schachter, Jacob, Long, Georgina V., Hodi, F. Stephen, Wolchok, Jedd D., Arance, Ana, Jacques Grob, Jean, Joshua, Anthony M., Weber, Jeffrey S., Mortier, Laurent, Jensen, Erin, Diede, Scott J., Homet Moreno, Blanca, Ribas, Antoni
Publicado 2021

Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial

por Gonzalez-Cao, Maria, Mayo de las Casas, Clara, Oramas, Juana, Berciano-Guerrero, Miguel A., de la Cruz, Luis, Cerezuela, Pablo, Arance, Ana, Muñoz-Couselo, Eva, Espinosa, Enrique, Puertolas, Teresa, Diaz Beveridge, Roberto, Ochenduszko, Sebastian, Villanueva, Maria-Jose, Basterretxea, Laura, Bellido, Lorena, Rodriguez, Delvys, Campos, Begoña, Montagut, Clara, Drozdowskyj, Ana, Molina, Miguel A., Lopez-Martin, Jose Antonio, Berrocal, Alfonso
Publicado 2021